Gastrointestinal (GI) involvement is almost universal in patients with systemic sclerosis (SSc) and is associated with significant disease-related morbidity and mortality.1 The entire GI tract can be involved and other disease features (eg, low mood, terminal organ failure and functional hand impairment) can result in significant nutritional impairment. Severe GI involvement has been reported to occur in ~10% of patients with SSc and often occurs early in the course of the disease.2 However, identification of patients at high risk of clinically significant weight loss is extremely challenging, including from the high prevalence of GI symptoms in patients with SSc. Therefore, there is a need to understand high-risk patients including potentially modifiable risk factors, with a view to early intervention strategies. Against this background, the aim of this study was to examine potential clinical risk factors of significant weight loss in patients with SSc. We performed an analysis of patients with SSc enrolled in the multinational, longitudinal European League Against Rheumatism (EULAR) Scleroderma Trials and Research (EUSTAR) database. In our study, we defined significant weight loss as 4.5 kg and/or least 5% of their body weight at 5 months onwards.3 Patients with a recorded second visit after 3 months and before 12 months were included in the analysis. We adopted a pragmatic approach (relevant to clinical practice) in …

中文翻译：

---

系统性硬化症的显着体重减轻：来自 EULAR 硬皮病试验和研究 (EUSTAR) 数据库的研究

胃肠道 (GI) 受累在系统性硬化症 (SSc) 患者中几乎普遍存在，并且与显着的疾病相关发病率和死亡率相关。1 可能累及整个胃肠道和其他疾病特征（例如情绪低落、终末器官衰竭和功能性手部损伤）可能导致严重的营养障碍。据报道，大约 10% 的 SSc 患者会出现严重的胃肠道受累，并且通常发生在病程早期。2 然而，识别具有临床显着体重减轻高风险的患者极具挑战性，包括高患病率SSc 患者的胃肠道症状。因此，有必要了解高危患者，包括潜在可改变的危险因素，以期制定早期干预策略。在这样的背景下，本研究的目的是检查 SSc 患者体重显着减轻的潜在临床危险因素。我们对纳入多国纵向欧洲抗风湿病联盟 (EULAR) 硬皮病试验和研究 (EUSTAR) 数据库的 SSc 患者进行了分析。在我们的研究中，我们将显着的体重减轻定义为 5 个月后体重减轻 4.5 公斤和/或体重的至少 5%。3 记录在 3 个月后和 12 个月前第二次就诊的患者被纳入分析。我们在……中采用了务实的方法（与临床实践相关）纵向欧洲抗风湿病联盟 (EULAR) 硬皮病试验和研究 (EUSTAR) 数据库。在我们的研究中，我们将显着的体重减轻定义为 5 个月后体重减轻 4.5 公斤和/或体重的至少 5%。3 记录在 3 个月后和 12 个月前第二次就诊的患者被纳入分析。我们在……中采用了务实的方法（与临床实践相关）纵向欧洲抗风湿病联盟 (EULAR) 硬皮病试验和研究 (EUSTAR) 数据库。在我们的研究中，我们将显着的体重减轻定义为 5 个月后体重减轻 4.5 公斤和/或体重的至少 5%。3 记录在 3 个月后和 12 个月前第二次就诊的患者被纳入分析。我们在……中采用了务实的方法（与临床实践相关）